AFT Pharmaceuticals hits $200m revenue milestone despite profit dip

AFT Pharmaceuticals hits $200m revenue milestone despite profit dip
AFT co-founder Dr Hartley Atkinson says launching into new markets takes time to reap rewards. (Image: AFT Pharmaceuticals)
Rebecca Stevenson
AFT Pharmaceuticals' co-founder, Dr Hartley Atkinson, says the firm’s choice to invest in Australia has been vindicated. The dual-listed pharmaceutical company released its results for the year ended March 31 on Thursday. While profit after tax fell to $11.9 million, revenue cracked $200m for the first time. Revenue from Australia increased by 17% to $127.1m, and operating profit leapt 65% to $25.5m. Chief executive Atkinson said AFT's investment in Australia had caused some concern, but the result proved its strate...

More Markets

Vulcan Steel leads as reporting season approaches
Markets Market Close

Vulcan Steel leads as reporting season approaches

The S&P/NZX 50 Index closed 55.30 points higher at 12,889.38.

Jamie Gray 15 Aug 2025
Competition law changing to allow 'beneficial collaboration'
Markets

Competition law changing to allow 'beneficial collaboration'

Confidential submissions to the Commerce Commission will get a 10-year OIA exemption.

Pattrick Smellie 15 Aug 2025
Small cap spotlight: Blackpearl Group
Markets Small Cap Wrap

Small cap spotlight: Blackpearl Group

Founder Nick Lissette says it's patriotic to be listed, but hard work.

NZ sharemarket rises, Vista Group shares fall
Markets Market Close

NZ sharemarket rises, Vista Group shares fall

The New Zealand sharemarket was up on Thursday as most stocks on the main board lifted.

Tom Raynel 14 Aug 2025